“True” Antiandrogens—Selective Non-Ligand-Binding Pocket Disruptors of Androgen Receptor–Coactivator Interactions: Novel Tools for Prostate Cancer

[Image: see text] Prostate cancer (PCa) therapy typically involves administration of “classical” antiandrogens, competitive inhibitors of androgen receptor (AR) ligands, dihydrotestosterone (DHT) and testosterone (tes), for the ligand-binding pocket (LBP) in the ligand-binding domain (LBD) of AR. Pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Caboni, Laura, Kinsella, Gemma K., Blanco, Fernando, Fayne, Darren, Jagoe, William N., Carr, Miriam, Williams, D. Clive, Meegan, Mary J., Lloyd, David G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2012
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295204/
https://www.ncbi.nlm.nih.gov/pubmed/22280402
http://dx.doi.org/10.1021/jm201438f

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295204/
https://www.ncbi.nlm.nih.gov/pubmed/22280402
http://dx.doi.org/10.1021/jm201438f

Ejemplares similares